Valuation: AP Biosciences, Inc.

Market Cap	11.11B 346M 303M 279M 259M 490M 32.82B 499M 3.35B 1.3B 16.17B 1.3B 1.27B 56.06B	P/E 2024	-8.86x	P/E 2025	-34.4x
Enterprise Value	9.99B 311M 272M 251M 233M 441M 29.54B 449M 3.01B 1.17B 14.55B 1.17B 1.14B 50.45B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	41.89%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : AP Biosciences, Inc.

05-15	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies	CI
03-31	AP Biosciences, Inc. has filed an IPO in the amount of TWD 1.2562 billion.	CI
03-23	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	AP Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/08/25	AP Biosciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
14/05/25	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/04/25	AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual Meeting	CI
22/04/25	AP Biosciences Doses First Patient In Phase 1/2 Clinical Trials Of AP402 For HER2+ Cancer Patients	RE
22/04/25	AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients	CI
21/04/25	AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting	CI
13/08/24	AP Biosciences Inc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
19/03/24	AP Biosciences Inc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

More news

Press Releases: AP Biosciences, Inc.

24/07/25

Designing antibodies to think before they bind

More press releases

Managers and Directors: AP Biosciences, Inc.

Manager	Title	Age	Since
Jeng-Horng Her CEO	Chief Executive Officer	-	27/05/2013
Shu Cheng Lin DFI	Director of Finance/CFO	-	18/10/2022
Wan Ju Tseng ADM	Chief Administrative Officer	-	18/10/2022

Director	Title	Age	Since
Chih Chuan Chen CHM	Chairman	-	23/05/2023
Jeng-Horng Her BRD	Director/Board Member	-	09/11/2022
Shih Ming Lin BRD	Director/Board Member	-	23/05/2023

More insiders

AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/07/26	NT$114.50	+9.57%	1,092,860
06/07/26	NT$104.50	-0.48%	602,760
03/07/26	NT$105.00	+7.69%	673,043
02/07/26	NT$97.50	+0.31%	93,903
01/07/26	NT$97.20	-3.76%	198,898

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Taipei Exchange Other stock markets 07/07/2026			5-day change	1st Jan Change
114.50 ^TWD	+9.57%		+14.61%	-36.39%

1 day	+9.57%
1 week	+14.61%
Current month	+13.37%
1 month	+9.05%
3 months	-43.18%
6 months	-34.57%
Current year	-36.39%

1 week	96	114.5
1 month	92.5	114.5
Current year	92.5	236
1 year	52.3	236
3 years	36.3	236
5 years	36.3	236
10 years	36.3	236

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AP BIOSCIENCES, INC.	+9.57%	+14.61%	+112.43%	-	279M
ARGENX SE	-0.10%	+0.10%	+74.33%	+133.26%	57.73B
WUXI APPTEC CO., LTD.	-3.80%	-6.24%	+67.04%	+86.36%	54.69B
BIONTECH SE	+0.38%	+1.33%	-14.32%	-11.76%	23.75B
INSMED INCORPORATED	+1.17%	+5.83%	+16.39%	+468.18%	24.18B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	+4.25%	+40.38%	-3.72%	19.82B
GENMAB A/S	+3.78%	+5.65%	+44.99%	-26.23%	17.14B
PHARMAESSENTIA CORPORATION	+3.46%	+17.72%	+206.66%	+364.07%	16.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.81%	+18.00%	+41.99%	-	15.57B
EXELIXIS, INC.	+2.79%	+4.91%	+29.26%	+195.60%	13.96B
Average	+1.27%	+7.10%	+61.92%	+150.72%	24.39B
Weighted average by Cap.	-0.38%	+3.39%	+57.99%	+139.30%

	2024	2025
Net sales	-	-
Net income	-423M -13.16M -11.52M -10.62M -9.84M -18.66M -1.25B -19.01M -127M -49.53M -615M -49.4M -48.32M -2.13B	-445M -13.84M -12.12M -11.18M -10.35M -19.63M -1.31B -20M -134M -52.1M -648M -51.97M -50.84M -2.25B
Net Debt	-1.47B -45.78M -40.08M -36.96M -34.23M -64.92M -4.35B -66.13M -443M -172M -2.14B -172M -168M -7.42B	-1.11B -34.59M -30.29M -27.93M -25.87M -49.06M -3.28B -49.97M -335M -130M -1.62B -130M -127M -5.61B

AP Biosciences, Inc. Stock

Stocks

6945

TW0006945009

Biotechnology & Medical Research

Valuation: AP Biosciences, Inc.

Chart: AP Biosciences, Inc.

Latest news : AP Biosciences, Inc.

Press Releases: AP Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AP Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates